Navigation Links
Use of Vitamin K Antagonists in the Treatment of Atrial Fibrillation is Driven by the Availability of an Oral Formulation, Cost and Widespread Inclusion on Guidelines and Formularies
Date:12/15/2010

MALVERN, Pa., Dec. 15, 2010 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that, in the treatment of atrial fibrillation, surveyed European cardiologists indicate that use of vitamin K antagonists, as a class, is primarily driven by the availability of an oral formulation, overall low cost and widespread inclusion on European medical society guidelines and hospital formularies. Vitamin K antagonists and low molecular weight heparins are the most commonly used anticoagulants across physician specialties in Europe.

"Orally administered vitamin K antagonists tend to dominate prescribing in both in-patient and discharge therapy setting, while low molecular weight heparins are more frequently used in the in-patient setting because of their injectable formulation," said AMR Analyst James Andersen.

The analysis can be found in Hospital Insight Series: Anticoagulants—Stroke Prevention in Atrial Fibrillation (Europe) which will publish later this month. The report analyzes the use of anticoagulants in atrial fibrillation using AMR's comprehensive and highly detailed clinical data in conjunction with primary research and extensive understanding of the market. This report contains European data and examines the reasons behind cardiologists' product preferences, factors driving anticoagulant prescribing patterns and physician receptivity to emerging treatments.

About AMRAMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-296-2597 ccomfort@dresources.com
'/>"/>

SOURCE Arlington Medical Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ChromaDex Partners With Kappa Bioscience to Provide Quality Control Methods, Tools and Services for Vitamin K2
2. FDA Cautions on Accurate Vitamin D Supplementation for Infants
3. Upsher-Smith Introduces New Formulation of PreNexa® Prenatal Vitamins
4. Mission Pharmacal Launches New Vitamin B6-Rich Prescription Prenatal Vitamin, CitraNatal(R) B-Calm
5. Upsher-Smith Announces New Formulation of PreNexa(R) Prenatal Vitamins
6. New Research Shows a Vitamin/Nutriceutical Formulation Improves Memory and Cognitive Performance in Community-Dwelling Adults
7. Vitamin E Improves NASH
8. FDA: Procter & Gamble Unlawfully Marketing Two Vicks Cold and Flu Medicines Containing Vitamin C
9. VitaminSpice Appoints Dr. Richard F. Seelig as Director
10. July 2009 Mayo Clinic Womens HealthSource Highlights Food Storage Safety, Energy Therapies and Vitamins and Minerals
11. Study Suggests Vitamin D Screening and Appropriate Supplementation Indicated for All Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... , May 23, 2016 ... Devices, Diagnostics and Monitoring, and Vision Care ... Which areas are going to grow at the fastest ... revenues to 2026, assessing data, trends, opportunities and prospects. ... charts, and graphs. Discover the most lucrative areas in ...
(Date:5/23/2016)... , May 23, 2016 The ... USD 5.0 billion by 2022, according to a new ... of medical waste coupled with the lack of centralized ... expected to drive the demand for reprocessed medical devices ... as compared to that of the original device is ...
(Date:5/20/2016)... LONDON , May 20, 2016 ... for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant ... Emerging Biological Drugs - This New Study Reveals ... Stay Ahead ,What is the ... get the latest technological and commercial analysis. Staying ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... 25, 2016 , ... HealthPostures , a national ergonomics ... engineers at the American Society of Safety Engineers Conference in Atlanta, Georgia. The ... Engineers, speakers and exhibitors from more than 40 countries are scheduled to appear ...
(Date:5/24/2016)... ... May 24, 2016 , ... Sterling Global Products is ... unique and patented refillable hanging wipe dispenser. The campaign kick-off video is located via ... end June 25, 2016. The goal is to raise $1,000 per day for a ...
(Date:5/24/2016)... ... May 24, 2016 , ... Fire Door ... provide one resource, from start to finish, for Life Safety compliance. These ... Condition surveys requested by the Joint Commission, and fire stopping reviews, inspections, and ...
(Date:5/24/2016)... ... May 24, 2016 , ... United Benefit Advisors (UBA), ... Partner Firm Austin & Co., Inc. Headquartered in Albany, New York, Austin ... consulting, benefits technology, and beyond. As an employee-owned company celebrating over 160 ...
(Date:5/24/2016)... VA (PRWEB) , ... May 24, 2016 , ... How ... 2016 · Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to be ... unlikely that human error will ever be totally eliminated, many human performance problems can ...
Breaking Medicine News(10 mins):